ORTIVUS INFORMS ABOUT A POSSIBLE MANDATORY BID FROM PONDERUS INVEST
Idag, 15:30
Ortivus Aktiebolag (“Ortivus” or the “Company”) resolved at an extraordinary general meeting on September 19, 2025 to carry out a fully guaranteed rights issue of B shares corresponding to an issue amount of approximately SEK 54 million (the “Rights Issue”). As a result of the subscription and guarantee commitments that Ponderus Invest AB provided in connection with the Rights Issue, Ponderus Invest AB subscribed for and was allotted a total of 42,255,022 B shares. As Ortivus has previously announced, Ponderus Invest’s ownership hereafter amounts to 61 percent of the shares and 53 percent of the votes (80,525 A shares and 53,604,716 B shares). The mandatory bid threshold has thus been exceeded (according to the Takeover rules for certain trading platforms adopted by the Swedish Stock Market Self-Regulation Committee).
Ponderus Invest AB intends to provide information about a possible mandatory bid after Ortivus' quarterly report Q3 2025, which will be published on November 28, 2025, but no later than December 3, 2025.
Contacts
For further information, please contact
Johan Wewel, CFO
Phone +46 8 446 45 00
About Ortivus
Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.
Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.
Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.
Read more about our solutions at www.ortivus.com
Attachments
ORTIVUS INFORMS ABOUT A POSSIBLE MANDATORY BID FROM PONDERUS INVEST
ORTIVUS INFORMS ABOUT A POSSIBLE MANDATORY BID FROM PONDERUS INVEST
Idag, 15:30
Ortivus Aktiebolag (“Ortivus” or the “Company”) resolved at an extraordinary general meeting on September 19, 2025 to carry out a fully guaranteed rights issue of B shares corresponding to an issue amount of approximately SEK 54 million (the “Rights Issue”). As a result of the subscription and guarantee commitments that Ponderus Invest AB provided in connection with the Rights Issue, Ponderus Invest AB subscribed for and was allotted a total of 42,255,022 B shares. As Ortivus has previously announced, Ponderus Invest’s ownership hereafter amounts to 61 percent of the shares and 53 percent of the votes (80,525 A shares and 53,604,716 B shares). The mandatory bid threshold has thus been exceeded (according to the Takeover rules for certain trading platforms adopted by the Swedish Stock Market Self-Regulation Committee).
Ponderus Invest AB intends to provide information about a possible mandatory bid after Ortivus' quarterly report Q3 2025, which will be published on November 28, 2025, but no later than December 3, 2025.
Contacts
For further information, please contact
Johan Wewel, CFO
Phone +46 8 446 45 00
About Ortivus
Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.
Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.
Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.
Read more about our solutions at www.ortivus.com
Attachments
ORTIVUS INFORMS ABOUT A POSSIBLE MANDATORY BID FROM PONDERUS INVEST
Nibes rapport
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Nibes rapport
Mest läst
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Marknadsöversikt
1 DAG %
Senast
1 mån
